The U.S.-listed shares of Danish drugmaker Novo Nordisk rose Tuesday following a report that an activist investor is building ...

Activist hedge fund Parvus Asset Management is building a stake in Novo Nordisk amid investor concerns that the Danish ...

Novo Nordisk’s shock decision to oust its chief executive has resulted in the Ozempic maker once again becoming Europe’s ...

Novo Nordisk jumps 5% as Parvus Asset Management builds a stake to sway CEO succession amid leadership shakeup and pipeline ...

Novo Nordisk ( NVO 6.12%) stock, maker of the blockbuster GLP-1 agonist weight-loss drugs Ozempic and Wegovy, jumped a lucky ...

Novo Nordisk (NYSE:NVO) rose to its highest level in over two months Monday after a media report said hedge fund Parvus Asset ...

Hedge fund aims to influence CEO appointment as drugmaker battles share price slump and competition from Eli Lilly.

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Novo Nordisk (NVO) shares hit their highest level in over two months following a Financial Times report that activist hedge ...

According to the article, that investor aims to influence the company's choice of a chief executive.